Bristol-Myers Squibb (BMY) Completes Acquisition of RayzeBio (RYZB) Feb 26, 2024 08:36AM
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform Feb 26, 2024 08:35AM
Bristol-Myers Squibb (BMY) Announces Expiration of Tender Offer for RayzeBio Feb 23, 2024 06:59AM
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer Feb 23, 2024 06:59AM
Bristol-Myers Squibb (BMY) and RayzeBio (RYZB) Announce Expiration of HSR Act Waiting Period Feb 12, 2024 06:59AM


Feb 12, 2024 06:59AM Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Dec 26, 2023 07:13AM Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Dec 26, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 Billion
Dec 26, 2023 06:59AM  Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio